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The multiple-dose pharmacokinetics of ceftazidime (CAZ) (administered twice daily in a 50 mg/kg of body weight i.v. dose) were studied in 10 seve rely asphyxiated term infants with suspected septicemia on d 3 of life. Nine term infants with suspected septicemia but without asphyxia served as controls. Blood samples were collected from an arterial catheter at 0, 0. Perinat al asphyxia is a result of complicated or traumatic deliveries and may exert profound effects on renal and liver function. McCance and Widd owson (1) reported as early as 1954 a reducti on in the GFR, a poor urea clearance , and a low urine output in full-term and postmature infants after prolonged and difficult labor. A redistribution of the fetal circulation leading to an increas ed blood flow to the brain, heart, and adrenals and a concomitantly decrea sed blood flow to the lungs, intestines, and kidneys is responsi ble for this asphyxiainduced renal impairment (2) . Several drugs such as the f3-l actam antibiotic CAZ are primar ily excrete d by the kidneys. CAZ, a broad spectrum cephalosporin, is an antibiotic frequentl y used for the treatment of infectious diseases in newborn infants. The currently recommended dosage for CAZ in term infants is 50-150 mglkg of body weight per day in two or three daily doses (3, 4) . The dosage and dosing interval of CAZ will be influenced by changes in GFR such as those caused by asphyxia. However, pharmacokinetic studies in asphyxiated newborns have not been performed. Hence, recomm endations to adjust drug dosages of CAZ are not available. We therefore examined the impact of asphyxia on the disposition characteristics of CAZ in the term newborn.
METHODS

Patients.
Ten term infants with severe asphyxia were included in this study. All infants met the criteria as recently defined by the Am erican College of Obstetricians and Gynecologists and the American Ac ademy of Pediatrics Committees on Maternal-Fetal Medicine and Fetus and Newborn (5) . All of the following were present: profound umbilical artery acidemia (pH < 7.00), persistence of an Apgar score of 0-3 longer than 5 min, neonatal neurologic sequelae (e.g. seizures, coma, hypotonia), and multiorgan system dysfunction (e.g. cardiovascular, gastrointestinal, hematologic, pulmon ary, or renal). Nine ASPHY XIA AND CEFTAZIDIME PHARMACOKINETICS 809 term infants without asphyxia served as cont rols. Five of these infants had meconium aspiration syndro me but normal Apga r scores and an umbilical arterial pH above 7.15, and four had transient tachypnea of the newborn. Inf ants receiving nephrotoxic or inotropic drugs were excluded. All infants had an indwelling radial artery catheter. The study protocol was approved by the Medical Ethica l Committee of the Unive rsity Hospit al Rotterdam. Patients were enr olled only after informed consent was obtained from the parents. All infant s received because of suspected septicemia dire ctly from birth 50 mg/kg of body weight CAZ and 50 mglkg of body weight amoxicillin i.v. every 12 h as a bolu s inje ction. In patients with sterile blood cultures and with out a focus of infection the therapy was discontinued after 72 h.
Pharmacokinetic study. The multiple-d ose pharmacokinetics of CAZ were studi ed on d 3 after birth because antibiotic trea tment was stopped after 72 h in infants with sterile blood cultures . Blood samples we re taken from indwelling arteria l lines before an i.v. bolu s injection of CAZ (t = 0) and at 0.5, 1, 2, 4, 8, and 12 h after the administration. Th ese sampling times we re selected based on the known dispos ition profile for CAZ. Serum samples obtained after centri fugation (Merck type Eppendorf 5414 , 3000 X g for 1 min) were stored at -70°C.
Measur ement oj the CFR. The GFR was measured on d 3
after birth by means of the continuous inulin infusion technique (6, 7) . A 10% glucose-inulin solution cont aining 25 g of inulin per liter was infused at a rate of 0.6 mL/kglh , beginning at time (t) zero of the pharm acokinetic study . Aft er 24 h, the inulin clearance (CL in) was calculated from the infusion rate (R), the inulin concentra tion in the infusate (1) , and the serum inulin conc entration (Pin) by the equation cr., = (I ' R)/P in . T he determination of inul in in serum was performed after acid hydrol ysis in 0.3 mmol/L perchloric acid for 15 min at 70°C. The fruct ose thus form ed was measured enzymatically acco rding to Beutler (8) .
Ceftazidime assay. An alysis of serum CAZ concentrations was performed according to the meth od described by Ayrton (9) with minor modifi cations. HPLC-grade acetonitrile was purchased from Rathbu rn (Walkerburn, Sco tland). Th e other chemicals we re pur chased from Aldrich-Chemie (Steinheim, Germ any). All chemicals applied were of the highest grade co mmercia lly available. Chromatographic anal ysis was performed with a glass-prepacked C 18 column (100 by 8 mm , Resolve Radial Pak, Waters, Rochester, MN) combined with a guard colu mn . A Waters model 6000 chromatography pump was used to deliver the eluent: 4.8% (vo l/vol) acet onitrile, 13.5 % methanol in 20 mM so dium acetate buffer (pH 3.6) at a flow rate of 2 mL/min. Th e separations were carried out at room temperatur e. The eluate was monitored with two Waters absorbance detectors (model 440/wavelength of 254 nm and model 484/wavelength 265 nm.
To a 50-p,l aliquot of the serum sample, an equal volume of 6% (vol/vol) perchl oric acid containing 50 mglL cephaloridine as an intern al standard was added. Samples were centrifuged at 1500 g for 5 min (Eppendorf centrifuge 5412). Subsequently 25 JLL were transferred by an automatic sample injector (WISP 710 B; Waters) to the column .
A calibr ation curve was made by dissolving 4, 12, 25, 50, 100 , 200, and 400 JLg CAZ per mL in serum. Th ese spiked standard samples we re processed accor ding to the procedure menti oned above. A linear calibration curve was obtained over a rang e of 4 to 400 JLg of CAZ/mL. Spiked samples of the calibration curve underwent the sam e processing proc edure as clinical samples. Hence, clinical samples we re directl y converted from the calibration cur ve to actual CAZ co ncentrations per mL of serum. The lower limit of detect ion of CAZ in serum was 0.5 mg/L. The coefficients of interassay var iation at different con centr ations we re less than 7%. The intraassay values were less than 5%. Recovery of 95% of CAZ, which had been incubated for 24 h at room temp erature, was establi shed. To examine different dosing strat egies, based on the assumption that serum concentr ations should never drop below 5 mglL , dosage recomm endations for CAZ were calculated using the followi ng equatio n:
Pharmacokinetic analysis.
In this formul a C.,. is the serum trough concentration, D the pres cribed dose in mglk g, wt the we ight in kg, k the elimination rate constant, T the dosing interval in h, Y the apparent volume of distribution of CAZ.
Statistical analysis. Data given are mean ± SD unless indi cated otherwise . Correlation coefficients are Pearson 's. Continuous data we re co mpared using the Mann-Whitney test. 
RESULTS
Th e demographic and clinical parameters of all infants
(asphyxiated versus nonasphyxiated) are shown in Table 1 .
Non e of the infants in both groups had a positive blood culture.
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Value s are mea n :': SO. CL, tota l body clearance; V, apparent volume of dist ribution; 11/2' elimination serum half-life, CLin, inulin clearance; NS, not significant. The data presented in this study indicate that asphyxia in term infants results in a significant decrease in the GFR as measured by the CL in . The positive relationship (r = 0.87, p < 0.001) between the GFR and the CAZ clearance indicates the important role of the GFR in the clearance of CAZ. The decrease in the GFR results in a significant decrease in the CAZ clearance and a concomitant increase of t 'h of CAZ and serum trough levels (46 ± 14 mg/L) in the asphyxiated infants .
These results indicate that twice daily administration of 50 mg/kg CAZ to term asphyxiated newborns results in high serum concentrations of CAZ during the entire dosing interval. An optimal dose regimen should result in a high clinic al efficacy and a minimal degree of toxicity. To ensure clinical efficacy the serum concentrations of CAZ should be above the minimal inhibitory concentration (MIC) of CAZ for major neonatal pathogens such as Streptococcus aga lactiae (MIC 9o < 0.25 mg/L) and Escherichia coli (MIC 9o < 0.25 mg/L) (11, 12) . The serum levels of CAZ in the current study were far above the MICs during the entire dosing interval. Therefore modification of the CAZ dose in the asphyxiated newborn is t Significantly different (p < 0.01) from contro ls. The pharmacokinetics of CAZ and the CL in are shown in Table  2 . Figure 1 Based on the assumption that serum concentrations should never drop below 5 mg/L, using the equation given in the method s section, dosage recommendations for CAZ were calculated. not indicated to improve clinical efficacy. However, f3-lactam antibiotics are all neurotoxic to some extent (13, 14) . Several factors have been identified or suggested to contribute to the neurotoxicity of the f3-lactam antibiotics: excessive dosage, renal insufficiency, disruption of the blood-brain barrier, preexisting CNS diseases , and competitive inhibition of the transport system that exports f3-lactam antibiotics out of the CNS. In adults CAZ has been reported to cause encephalopathy, hallucinations, confusion, and neuromu scular excitability (15) (16) (17) (18) (19) . In the rat model, a dose-dependent suppr essive effect of f3-l actam antibiotics has been demonstrated on the differentiation and proliferation of oligodendrocytes (20) .
Asph yxia neonatorum is associated with an impaired renal function, which will result in high serum levels of CAZ. CSF acidosis and an increased CSF lactate level may lead to an impaired capacity to export f3-lactam antibiotics out of the CNS, resulting in accumulation of the drug inside the CSF. Finally cerebral edema, hypoxia, and ischem ia will make the brain more vulnerable for neurotoxicity. In our study we could not detect CAZ-related neurotoxicity because asphyxia in itself was responsible for neurologic sequelae in the immediate neonatal period including seizures, hypotoni a, coma , or hypoxic -ischemic encephalopathy. Althou gh no CAZ-rel ated side effects could be demonstrated in this study, the data described above indicate that modification of the dose of CAZ in the asphyxiated newborn should be perform ed to prevent potential drug-indu ced neuroto xicity.
We decided to use a model in which a trough level of 5 mg/L was chosen as the minimum level desired for appropriate bacteri al killing of the most important neonatal microorganisms. Two different strategies were used for the calcul ations. Dosage recommendat ions were calculated using a fixed dosing interval of 12 h, which resulted in a CAZ dose of 25 mg/kg every 12 h. Alternati vely appropriate dosing could also be achieved by extending the dosing interval to 18 h using a CAZ dose of 50 mg/kg. We conclude that asphyxia has a significant impact on the dispositi on characteristics of CAZ in the term newborn and that dosage adjustments of CAZ are indicated in term asphyxiated infants with a decreased GFR. Further studies are needed to examine the impact of asphyxia on the disposition of drugs with extensive renal clearance like CAZ. In addit ion the impact of asph yxia on the disposition of drugs with extensive nonrenal clearance like theophylline also needs to be investigated.
